/l. Blood film showed medium to large blasts with occasional hand-mirror forms. Bone marrow biopsy demonstrated over 90% lymphoid blasts (cCD3+, CD2/4/7/8+, CD34-, CD1a+, TdT+ on flow cytometry) in keeping with cortical T-cell ALL. Karyotype was normal but loss of 1 copy of ETV6 (12p13) was detected by fluorescence in-situ hybridisation. Central nervous system (CNS) involvement was confirmed with meningeal thickening and enhancement on magnetic resonance imaging (MRI) and the presence of lymphoblasts in cerebrospinal fluid (CSF). The patient was treated according to the UKALL XIV trial in which the T-cell arm explores the role of nelarabine in consolidation (ISRCTN 66541317), but was randomised to receive standard therapy alone. Twice weekly intrathecal methotrexate was administered until CSF blast clearance.
The patient achieved complete remission (CR) following phase 1 induction, including no minimal residual disease (MRD; <10 ) detected by flow cytometry. He underwent HLA-matched sibling allogeneic HSCT for high-risk disease (based on high diagnostic WBC) in September 2014, following phase 2 induction. Standard conditioning with total body irradiation potentially exposed this patient, with over 80 subcutaneous neurofibromata, to an increased risk of secondary malignancy [2] . An individualised regimen using fludarabine and IV busulphan (4 days) was implemented, with 24 Gy cranial radiotherapy pre-HSCT for CNS disease. Transplant course was uncomplicated, with no acute or chronic-graft-versus-host disease (GVHD). Bone marrow biopsy at day 100 demonstrated ongoing CR by flow cytometry.
The patient was noted to have mixed peripheral blood chimerism (whole blood 97%, T-cell 79%, myeloid 97%) 3 months post-HSCT. Ciclosporin was weaned and a DLI (dose 1 × 10 6 CD3 cells/kg) administered on day 285. Tcell chimerism improved to 98% donor. In view of the notable absence of GVHD, a second DLI was administered 9 months post-HSCT (dose 1 × 10 7 CD3 cells/kg) in June 2015. The patient re-presented shortly following this with diplopia. MRI revealed enlargement of the right lateral rectus muscle, confirmed as T-ALL relapse on biopsy. Cardiac MRI, performed following an abnormal echocardiogram, demonstrated diffuse cardiac infiltration. Leukaemic blasts were detected in CSF (0.06 cells/ml) and 0.09% T-lymphoblasts with the diagnostic phenotype by bone marrow flow cytometry.
The patient appeared to have a poor prognosis, but in view of his excellent performance status, nelarabine was commenced in July 2015 at a dose of 1.5 g/m 2 on days 1, 3 and 5. The patient remained on continuous cardiac monitoring for cycle 1 given the potential for arrhythmias. Intrathecal cytosine arabinoside was administered twiceweekly. Diplopia rapidly improved and repeat orbital and cardiac MRIs, performed on days 14 and 24 respectively, showed complete resolution of all extramedullary lesions. 7 CD3 cells/kg), with no associated GVHD. Treatment with nelarabine was stopped in December 2015 owing to grade 3 paraesthesia and allodynia across the patient's anterior thorax. Over the following months, he also developed episodic left lower leg and foot numbness which progressed to involving his left arm and left side of his face. On examination, there was a left T7 sensory level. The patient had extensive neurological investigations with salient findings including: CSF cytospin and flow cytometry negative, CSF viral PCR negative (HSV, VZV, EBV, CMV, enterovirus and HHV6), endocrine, metabolic and autoimmune panels negative, MRI brain normal and T2-weighted MRI spine showing subtle high T2 intensity within the grey matter structures at T6-7. A presumptive diagnosis of nelarabine-induced myelopathy was made. The patient reported gradual improvements in his paraesthesia, and is now symptom-free.
Trilineage chimerism analysis has consistently demonstrated 100% donor cells since the patient's second DLI. He remains in complete remission, now over 2 years following relapse, is working 4 days per week and leading a full and active life.
This unique case highlights the difficult management decisions surrounding relapse of T-cell ALL following HSCT. With a median survival of only 5.5 months and less than 7% of patients alive at 5 years [3] , it remains a significant therapeutic challenge with novel strategies required.
Historically options in relapsed ALL were limited to regimens such as FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin), resulting in 6 months median overall survival (OS) in the small proportion of responders [4] . An improved understanding of the biology of the disease has allowed the identification of rational molecular targets in B-cell ALL and the emergence of novel immunotherapies, including blinatumomab (anti-CD19; CR in 46%) and inotuzumab ozogamicin (anti-CD22; CR in 81%) [5, 6] . Chimeric antigen receptors (CARs), redirecting T cells to the CD19 antigen, have also demonstrated remarkable potency with CR rates over 90% in relapsed/refractory B-ALL [7] . However, parallel approaches using CARs in T-ALL are impeded due to shared expression of targetable surface antigens between normal and malignant T cells, leading to fratricide of the CAR T cells and profound immunodeficiency [8] . Options for targeted therapy in T-ALL remain limited, and patient outcomes reflect this.
Nelarabine, a purine nucleoside analogue, is the only new drug licensed specifically for use in relapsed/refractory T-ALL. Response rates of 41% are reported, with 28% 1-year OS [9] ; however its efficacy in the post-HSCT population is less well described. A retrospective analysis of 11 patients receiving nelarabine as salvage therapy (including 5 as the sole agent) for relapse after HSCT demonstrated an overall response rate of 81%, with event free survival and OS at 1 year of 70% and 90% respectively [10] . We have been able to obtain longer term follow-up data for 6 out of the 11 patients in this study. Five patients, all treated in first relapse after HSCT, remain in CR2 at the time of writing (4-10 years post relapse). The remaining patient, who was treated in second relapse, had disease recurrence after 2 years and has subsequently died.
Of the five surviving patients described, three received DLIs after achieving CR with nelarabine-based regimens. Indeed, the existence of a graft-versus-leukaemia (GVL) effect in ALL is well established, with acute and/or chronic GVHD associated with a 2.5-fold reduction in ALL relapse rates [11] . However, outcomes using DLIs for salvage of overtly relapsed ALL have previously been disappointing. In a US study of 44 patients with relapsed ALL treated with DLIs, only 3 patients obtained remissions of a year or more, with uniformly poor outcomes irrespective of whether DLIs were administered in the nadir of vincristine-based chemotherapy or not [12] . In contrast, cytoreductive chemotherapy is successfully utilised in relapsed myeloid malignancies prior to immune modulation with DLIs, but it is necessary to achieve CR pre-DLI in order to demonstrate improved OS [13] . Accordingly, in the case described, nelarabine was used to induce remission prior to consolidation with DLIs, and we propose this as a strategy for enabling DLIs to obtain durable responses in T-ALL.
There are important considerations in the administration of nelarabine and DLI. Firstly, the timing of chemotherapy around DLIs needs to be carefully planned, to ensure minimal exposure of the circulating lymphocytes to cytotoxic agents. Cycle 4 of nelarabine was delayed to 4 weeks following DLI in this case, to avoid the peak myelosuppressive effects of chemotherapy. Secondly, nelarabine has been associated with significant, even fatal, dose-dependent central and peripheral neurotoxicity. At the recommended adult dose of 1.5 g/m 2 , the incidence of motor and/or sensory peripheral neuropathy is 21% [14] . As with many cases of relapsed ALL, our patient had already suffered numerous neurological insults, including his history of NF1, CNS disease, cranial irradiation and intrathecal chemotherapy. Although paediatric data suggest no association between nelarabine-induced neurotoxicity and concurrent intrathecal therapy or prior CNS irradiation [15] , we took a cautious approach with close monitoring for adverse effects and avoidance of further intrathecal methotrexate. The SPC for nelarabine recommends cessation of the drug with toxicities of grade 2 or above; we adhered to this.
We conclude that the combination of nelarabine and DLIs offers a promising approach in T-ALL that has relapsed post-HSCT, where treatment options are otherwise very limited. The optimum dose and schedule of both nelarabine and DLIs require further evaluation in largerscale studies.
